Showing results (191-200 of 344) with videos related to

Sort By:
Pageof 35
The Pediatric Infectious Disease Journal|April 28, 2009
Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive childrenHumberto Bracco Neto, Calil K Farhat, Miguel Wenceslao Tregnaghi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 29, 2009
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotypeGeorge P Christophi, Michael Panos, Chad A Hudson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2019
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsNicholas Kitchin, Shon A Remich, James Peterson, et al.
Cancer Research|January 14, 2014
VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiationAnna Fantozzi, Dorothea C Gruber, Laura Pisarsky, et al.
Human Vaccines & Immunotherapeutics|March 4, 2021
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of ageBrandon Essink, James Peterson, Kari Yacisin, et al.
Vaccine|February 2, 2017
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodiesElizabeth Begier, David Joshua Seiden, Michael Patton, et al.
The Pediatric Infectious Disease Journal|March 19, 2024
A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of AgeJay Meyer, Peter Silas, G Laïssa Ouedraogo, et al.
The Pediatric Infectious Disease Journal|October 1, 2011
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in CanadaOtto G Vanderkooi, David W Scheifele, Douglas Girgenti, et al.
The Pediatric Infectious Disease Journal|July 19, 2017
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6-17 Years of Age in India: An Open-label TrialSharad Agarkhedkar, Christine Juergens, Krishnamurthy Balasundaram, et al.
Clinical and Vaccine Immunology : CVI|May 2, 2008
Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young childrenBruce D Forrest, Michael W Pride, Andrew J Dunning, et al.
Pageof 35